Literature DB >> 21376504

Assessment of the effect of surgery on the kinetics of circulating tumour cells in patients with operable breast cancer based on cytokeratin-19 mRNA detection.

M Daskalakis1, D Mavroudis, E Sanidas, S Apostolaki, I Askoxylakis, E de Bree, V Georgoulias, J Melissas.   

Abstract

AIMS: The aim of this study was to evaluate the effect of surgery on the kinetics of CTCs in breast cancer patients.
METHODS: The detection of CK-19 mRNA-positive CTCs in the blood by RT-PCR was analysed in 104 stage 0-IIIA patients at 4 time-points: prior to surgery, upon completion, 24 h after surgery and 15 days after surgery. Furthermore, a late sample was assessed prior to initiation of adjuvant chemotherapy in a subgroup of 53 patients. As negative controls, peripheral blood was obtained from 50 female patients undergoing excision of benign breast lesions and from 11 female patients receiving surgery for early-stage colorectal cancer.
RESULTS: A significant percentage of blood samples from breast cancer patients (14.4%) were negative for CK-19 preoperatively but turned transiently positive early postoperatively. However, no significant difference in CK-19 mRNA detection was noted among the first 4 examined time-points. There was no significant correlation between CK-19 mRNA-positive cells and classic prognostic factors. A significant increase in CK-19 mRNA-positivity (32.1%) was observed in a late sample of the subgroup of 53 patients before adjuvant chemotherapy after a median of 54 days, postoperatively.
CONCLUSIONS: Surgery may result in CTC detection in a small proportion of early breast cancer patients. There is no clear correlation to indicate which patients are expected to have detectable CTCs. Although CTCs are detected in a small proportion of patients during the perioperative period, the detection rate may increase over time and with longer follow-up.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376504     DOI: 10.1016/j.ejso.2011.02.003

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  9 in total

Review 1.  Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?

Authors:  Olga A Martin; Robin L Anderson; Kailash Narayan; Michael P MacManus
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

Review 2.  Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects.

Authors:  Yuval Shaked
Journal:  Nat Rev Clin Oncol       Date:  2016-04-26       Impact factor: 66.675

3.  Circulating Tumor Cells Detected by RT-PCR for CK-20 before Surgery Indicate Worse Prognostic Impact in Triple-Negative and HER2 Subtype Breast Cancer.

Authors:  Seong Bae Hwang; Jeoung Won Bae; Hye Yoon Lee; Hoon Yub Kim
Journal:  J Breast Cancer       Date:  2012-03-28       Impact factor: 3.588

Review 4.  Reduction of breast cancer relapses with perioperative non-steroidal anti-inflammatory drugs: new findings and a review.

Authors:  Michael Retsky; Romano Demicheli; William J M Hrushesky; Patrice Forget; Marc De Kock; Isaac Gukas; Rick A Rogers; Michael Baum; Vikas Sukhatme; Jayant S Vaidya
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

5.  Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis.

Authors:  Wen-Ting Yan; Xiang Cui; Qing Chen; Ya-Fei Li; You-Hong Cui; Yan Wang; Jun Jiang
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

6.  Less micrometastatic risk related to circulating tumor cells after endoscopic breast cancer surgery compared to open surgery.

Authors:  Shichao Li; Wenting Yan; Xinhua Yang; Li Chen; Linjun Fan; Haoxi Liu; Kun Liu; Yi Zhang; Jun Jiang
Journal:  BMC Cancer       Date:  2019-11-08       Impact factor: 4.430

7.  Removal of Circulating Tumor Cells from Blood Samples of Cancer Patients Using Highly Magnetic Nanoparticles: A Translational Research Project.

Authors:  Simon Doswald; Antoine F Herzog; Martin Zeltner; Anja Zabel; Andreas Pregernig; Martin Schläpfer; Alexander Siebenhüner; Wendelin J Stark; Beatrice Beck-Schimmer
Journal:  Pharmaceutics       Date:  2022-07-01       Impact factor: 6.525

8.  Promising development from translational or perhaps anti-translational research in breast cancer.

Authors:  Michael Retsky; Romano Demicheli; William Jm Hrushesky; Patrice Forget; Marc De Kock; Isaac Gukas; Rick A Rogers; Michael Baum; Katharine Pachmann; Jayant S Vaidya
Journal:  Clin Transl Med       Date:  2012-08-28

9.  A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.

Authors:  Ruth S Weinberg; Marcelo O Grecco; Gimena S Ferro; Debora J Seigelshifer; Nancy V Perroni; Francisco J Terrier; Analía Sánchez-Luceros; Esteban Maronna; Ricardo Sánchez-Marull; Isabel Frahm; Marcelo D Guthmann; Daniela Di Leo; Eduardo Spitzer; Graciela N Ciccia; Juan Garona; Marina Pifano; Ana V Torbidoni; Daniel E Gomez; Giselle V Ripoll; Roberto E Gomez; Ignacio A Demarco; Daniel F Alonso
Journal:  Springerplus       Date:  2015-08-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.